Connected data gives you a clearer picture
At Evaluate we collect, calibrate and connect the pharmaceutical world's data.
Blog
Blog Library
Demystifying AI: Natural Language Processing (Part One)
Machine learning and artificial intelligence are increasingly-used buzzwords in the pharma and biotech space. But what's hiding in that black box?
Biotech Investment in 2022 : “You’ve got to kiss a lot of frogs”
The market may be tough, but with unprecedented innovation taking place, there's plenty for biotechs and investors to feel positive about in the long term
Q3 catalysts podcast: Evaluate Vantage hits the airwaves
Got time for a quick brain break? Listen to our podcast where we discuss the catalysts that will shape the third quarter of 2022.
BIO International 2022: Words from Space and Venus
Bio International was finally back for 2022. What did our first-timer to the event make of it?
Biotech terrain may be tricky, but it’s worth persevering
What are venture capitalists looking for from the biotech and pharma space?
Five reasons you can’t ignore payers during pipeline development
Could previously launched drugs that significantly missed sales expectations have met a different fate if their manufacturers had accounted for payer perspectives in…
ASCO 2022 Preview
ASCO 2022 kicks off this week, and a few days ago the abstracts for most of the presentations dropped.
Late to the party? Prepare to pay the price
I saw a tweet recently asking “in recent years, what has become simultaneously worse and more expensive?”. One wag responded with “life”, but I’d also argue that…
Networking on the Agenda at LSX World Congress
This week saw the return of the LSX World Congress in a real-life environment (London, to be precise).